Dr Reddy’s Laboratories gets Rs 2,395 crore show cause notice from IT authority
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Subscribe To Our Newsletter & Stay Updated